Duloxetine for fibromyalgia - horizon scanning review
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
NHSC. Duloxetine for fibromyalgia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
This study aims to summarise the currently available evidence on Duloxetine for fibromyalgia
Duloxetine (Yentreve, Cymbalta, LY 248686) is a dual serotonin and noradrenaline re-uptake inhibitor (SNRI) in phase III trials for the management of the symptoms of fibromyalgia. If successful in licensing it will be the first pharmaceutical licensed for fibromyalgia. Two 12 week randomised, placebo controlled trials in 207 patients and 354 women, found that duloxetine improved the Fibromyalgia Impact Questionnaire (FIQ) score, and Brief Pain Inventory 24-hour average pain score respectively. A phase III trial of duloxetine over 12 months is planned to start in October 2005 and will evaluate pain severity and patient-reported improvement in 320 women with fibromyalgia.